SO
GLUE icon

STRS Ohio’s Monte Rosa Therapeutics GLUE Stock Holding History

STRS Ohio’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$702K Buy
42,700
+6,600
+18% +$126K ﹤0.01% 846
2025
Q4 		$566K Buy
+36,100
New +$486K ﹤0.01% 974
2024
Q4 		– Sell
-3,100
Closed -$16.4K – 1945
2024
Q3 		$16.4K Hold
3,100
– – ﹤0.01% 1904
2024
Q2 		$11.6K Hold
3,100
– – ﹤0.01% 1916
2024
Q1 		$21K Buy
+3,100
New +$18.4K ﹤0.01% 1849
2022
Q2 		– Sell
-6,800
Closed -$95K – 2135
2022
Q1 		$95K Buy
6,800
+4,100
+152% +$56.9K ﹤0.01% 1855
2021
Q4 		$55K Hold
2,700
– – ﹤0.01% 1992
2021
Q3 		$60K Buy
+2,700
New +$77.4K ﹤0.01% 2040

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

STRS Ohio's GLUE Position: Q1 2026 in Review

STRS Ohio increased its Monte Rosa Therapeutics (GLUE) stake by 18% in Q1 2026, buying an estimated $126K and bringing the position to 42,700 shares worth $702K. The position accounts for ﹤0.01% of the portfolio, ranked #846.

STRS Ohio first reported a position in GLUE in Q3 2021 and has held it in 8 quarters since. 190 funds tracked by Wall St. Rank hold GLUE as of Q1 2026.

  • STRS Ohio held 42,700 shares of Monte Rosa Therapeutics worth $702K as of Q1 2026.
  • STRS Ohio bought 6,600 Monte Rosa Therapeutics shares in Q1 2026, an estimated $126K.
  • Monte Rosa Therapeutics made up ﹤0.01% of STRS Ohio's portfolio in Q1 2026, its #846 holding.
  • STRS Ohio first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • 190 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2026.

Based on STRS Ohio's 13F filing for Q1 2026, filed 24 Apr 2026.